Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 8:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 515 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Bronchitis Clear all
Completed Phase 2 Interventional

Pulmonary and Cardiac Effects of E-Cigarette Use in Pulmonary Patients Who Smoke Cigarettes

NCT05610514
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Chronic Bronchitis, Emphysema, Asthma-COPD Overlap Syndrome
Interventions
E-Cigarette, Financial Incentives
Other · Behavioral
Lead sponsor
University of Vermont
Other
Eligibility
40 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Feb 8, 2024 · Synced Oct 25, 2026, 8:44 AM EDT
Completed Phase 1 Interventional

A Study of GDC-0853 in Patients With Resistant B-Cell Lymphoma or Chronic Lymphocytic Leukemia.

NCT01991184
View directory record Official record
Conditions
Lymphocytic Leukemia, Chronic, Diffuse Large B-Cell Lymphoma
Interventions
GDC-0853
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
7
States / cities
Stanford, California • St Louis, Missouri • Columbus, Ohio + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2022 · Synced Oct 25, 2026, 8:44 AM EDT
Completed Phase 3 Interventional

To Evaluate the Long-term Safety of (R,R)-Formoterol in Subjects With COPD

NCT00064415
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Chronic Bronchitis, Emphysema
Interventions
arformoterol, Salmeterol
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
35 Years and older
Enrollment
799 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
90
States / cities
Anniston, Alabama • Birmingham, Alabama • Jasper, Alabama + 77 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2012 · Synced Oct 25, 2026, 8:44 AM EDT
Completed No phase listed Observational

Popcorn Lung: the Discovery of a New Disease

NCT00027235
View directory record Official record
Conditions
Lung Diseases, Interstitial, Bronchiolitis Obliterans
Interventions
Not listed
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 25, 2026, 8:44 AM EDT
Completed Phase 2 Interventional Results available

A Study of the Dosing, Efficacy, and Safety of Oral Cysteamine in Adult Patients With Cystic Fibrosis Exacerbations

NCT03000348
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Cysteamine, Placebo Oral Capsule
Drug
Lead sponsor
NovaBiotics Ltd.
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
8
States / cities
Tucson, Arizona • San Francisco, California • Gainesville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2021 · Synced Oct 25, 2026, 8:44 AM EDT
Completed No phase listed Observational

An Epidemiological Study to Evaluate the RSV-Associated Lower Respiratory Track in Infections in Infants

NCT00369759
View directory record Official record
Conditions
Respiratory Infections, Bronchiolitis, Pneumonia, Apnea
Interventions
Emergency Dept. Subjects with LRI or Apnea
Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
1 Day to 12 Months
Enrollment
2,048 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
38
States / cities
Phoenix, Arizona • Sylmar, California • Denver, Colorado + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2009 · Synced Oct 25, 2026, 8:44 AM EDT
Completed Phase 3 Interventional Results available

Long-term Safety, Tolerability and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-35)

NCT01044459
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Aclidinium Bromide 200 µg, Aclidinium Bromide 400 µg
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years and older
Enrollment
605 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
110
States / cities
Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 93 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2017 · Synced Oct 25, 2026, 8:44 AM EDT
Completed Phase 1 Interventional

Study of Individual Adult and Pediatric Patient Dose-escalated Interleukin-2 Therapy for Refractory Chronic GVHD

NCT02318082
View directory record Official record
Conditions
Chronic Versus Graft Host Disease
Interventions
Interleukin-2
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
2 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 23, 2020 · Synced Oct 25, 2026, 8:44 AM EDT
Recruiting No phase listed Observational

Deployment-Related Lung Disease Research Database and Biorepository

NCT03035097
View directory record Official record
Conditions
Bronchiolitis
Interventions
Biorepository
Other
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2030
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 25, 2026, 8:44 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Demonstration of Near Zero Antibiotic Prescribing for Acute Bronchitis

NCT01240174
View directory record Official record
Conditions
Bronchitis, Cough
Interventions
Demonstration of near zero antibiotic prescribing for patients with acute bronchitis
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 64 Years
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 1, 2017 · Synced Oct 25, 2026, 8:44 AM EDT
Completed Not applicable Interventional

Tai Chi After Pulmonary Rehabilitation in Patients With COPD: A Randomized Trial

NCT01998724
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Tai Chi, Group Walking
Behavioral
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
40 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 3, 2018 · Synced Oct 25, 2026, 8:44 AM EDT
Completed Phase 4 Interventional

Study of Nasal Irrigation Versus Nasal Spray for Chronic Nasal and Sinus Symptoms

NCT00318006
View directory record Official record
Conditions
Chronic Rhinosinusitis
Interventions
saline irrigation, saline spray
Procedure
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 30, 2015 · Synced Oct 25, 2026, 8:44 AM EDT
Terminated Phase 2 Interventional

A Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib

NCT04640025
View directory record Official record
Conditions
Myelofibrosis, Postlung Transplant (Bronchiolitis Obliterans), Chronic Graft Versus Host Disease
Interventions
itacitinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
8
States / cities
Duarte, California • Aurora, Colorado • Fort Wayne, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 25, 2026, 8:44 AM EDT
Withdrawn Phase 4 Interventional

Perforomist Versus Foradil Evaluated by Inspiratory Capacity and High Resolution Computed Tomography (HRCT)

NCT00633776
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, COPD, Chronic Bronchitis, Emphysema
Interventions
formoterol fumarate
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
40 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 4, 2016 · Synced Oct 25, 2026, 8:44 AM EDT
Recruiting Phase 2 Interventional

LAM-001 in Lung Transplant Recipients With Bronchiolitis Obliterans Syndrome.

NCT06018766
View directory record Official record
Conditions
Bronchiolitis Obliterans Syndrome, Chronic Lung Allograft Dysfunction, Lung Transplantation
Interventions
LAM-001, Placebo
Drug
Lead sponsor
Steven Hays, MD
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 25, 2026, 8:44 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults

NCT01667731
View directory record Official record
Conditions
Hepatitis C, Human Immunodeficiency Virus
Interventions
SOF, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
26
States / cities
Birmingham, Alabama • Coronado, California • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2014 · Synced Oct 25, 2026, 8:44 AM EDT
Completed Not applicable Interventional Results available

Optimizing Psychosocial Treatment of Interstitial Cystitis/Bladder Pain Syndrome

NCT04275297
View directory record Official record
Conditions
Chronic Interstitial Cystitis, Bladder Pain Syndrome, Cystitis, Interstitial, Painful Bladder Syndrome, Cystitis, Chronic Interstitial, Interstitial Cystitis, Interstitial Cystitis, Chronic, Interstitial Cystitis (Chronic) With Hematuria, Interstitial Cystitis (Chronic) Without Hematuria, Chronic Prostatitis, Chronic Prostatitis With Chronic Pelvic Pain Syndrome
Interventions
Psychosocial Treatment, Attention Control
Behavioral
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 8, 2023 · Synced Oct 25, 2026, 8:44 AM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)

NCT06619561
View directory record Official record
Conditions
Chronic Graft-Versus-Host Disease (cGVHD)
Interventions
Vimseltinib
Drug
Lead sponsor
Deciphera Pharmaceuticals, LLC
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
26
States / cities
Duarte, California • Los Angeles, California • Orange, California + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 25, 2026, 8:44 AM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38)

NCT01045161
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Aclidinium bromide, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years and older
Enrollment
544 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
110
States / cities
Birmingham, Alabama • Muscle Shoals, Alabama • Pell City, Alabama + 94 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2017 · Synced Oct 25, 2026, 8:44 AM EDT
Terminated Phase 2 Interventional Results available

A Proposal to Test the Efficacy and Tolerability of Bortezomib in Pulmonary Chronic GVHD

NCT01163786
View directory record Official record
Conditions
Bronchiolitis Obliterans
Interventions
Bortezomib
Drug
Lead sponsor
Northwestern University
Other
Eligibility
Not listed
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 10, 2020 · Synced Oct 25, 2026, 8:44 AM EDT
Withdrawn Phase 2Phase 3 Interventional

Efficacy of Magnesium Sulfate Bolus in Pediatric Patients With Bronchiolitis

NCT04740294
View directory record Official record
Conditions
Bronchiolitis, Viral
Interventions
Magnesium Sulfate
Drug
Lead sponsor
University of Louisville
Other
Eligibility
1 Month to 12 Months
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 25, 2026, 8:44 AM EDT
Completed Phase 2 Interventional Results available

Discontinuation or Continuation of Immunosuppressive Therapy in Participants With Chronic Graft Versus Host Disease

NCT03483675
View directory record Official record
Conditions
Chronic Graft Versus Host Disease
Interventions
Immunosuppressive Therapy, Survey Administration
Biological · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Not listed
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 23, 2021 · Synced Oct 25, 2026, 8:44 AM EDT
Completed Not applicable Interventional

Using Behavioral Science to Reduce Inappropriate Antibiotic Use in Acute Care Settings

NCT03711292
View directory record Official record
Conditions
Antimicrobial Stewardship, Acute Bronchitis, Upper Respiratory Infection
Interventions
Antibiotic Stewardship
Behavioral
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
21 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 23, 2023 · Synced Oct 25, 2026, 8:44 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Aerosol Liposomal Cyclosporine for Chronic Rejection in Lung Transplant Recipients

NCT01650545
View directory record Official record
Conditions
Disorder Related to Lung Transplantation, Bronchiolitis Obliterans, Decreased Immunologic Activity, Chronic Rejection of Lung Transplant
Interventions
Liposomal aerosol cyclosporine, standard immune suppression, oral
Drug · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 1, 2023 · Synced Oct 25, 2026, 8:44 AM EDT